On the dual roles and polarized phenotypes of neutrophils in tumor development and progression

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 3, 2012, Pages 296-309

  Piccard, H ^a,c   Muschel, R J ^b   Opdenakker, G ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

Cancer; Innate immunity; N1 N2 polarization; Neutrophil; Tumor microenvironment

Indexed keywords

BETA INTERFERON; CD11B ANTIGEN; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ONCOLYTIC VIRUS; PROTEINASE; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN ANTIBODY;

ABDOMINAL CANCER; ADAPTIVE IMMUNITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL AGGREGATION; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL POLARITY; CELL SURVIVAL; CHRONIC INFLAMMATION; CYTOLYSIS; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; EXTRAVASATION; GRANULOCYTE FUNCTION; HUMAN; IMMUNOREGULATION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; NEUTROPHIL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PHOTODYNAMIC THERAPY; REVIEW; TUMOR ASSOCIATED NEUTROPHIL; TUMOR IMMUNITY; TUMOR REJECTION; TUMOR VASCULARIZATION; VIRUS INFECTION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPHIL INFILTRATION; NEUTROPHILS; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84861190260     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.06.004     Document Type: Review

References (116)

1. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86:1065-1073.
2. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267:204-215.
3. Bodey B., Bodey B., Siegel S.E., Luck J.V., Kaiser H.E. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. Anticancer Res 1996, 16:3439-3446.
4. Caruso R.A., Bellocco R., Pagano M., Bertoli G., Rigoli L., Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 2002, 15:831-837.
5. Bodey B., Bodey B., Siegel S.E., Kaiser H.E. Immunocytochemical detection of leukocyte-associated and apoptosis-related antigen expression in childhood brain tumors. Crit Rev Oncol Hematol 2001, 39:3-16.
6. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010, 33:657-670.
7. Hirose K., Hakozaki M., Nyunoya Y., et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 1995, 72:708-714.
8. Van Coillie E., Van Aelst I., Wuyts A., et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am J Pathol 2001, 159:1405-1414.
9. Loukinova E., Dong G., Enamorado-Ayalya I., et al. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000, 19:3477-3486.
10. Opdenakker G., Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 2004, 48:519-527.
11. Schaider H., Oka M., Bogenrieder T., et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003, 103:335-343.
12. Lee L.F., Hellendall R.P., Wang Y., et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000, 164:2769-2775.
13. Bellocq A., Antoine M., Flahault A., et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998, 152:83-92.
14. Yao C., Lin Y., Ye C.S., Bi J., Zhu Y.F., Wang S.M. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl) 2007, 120:1766-1772.
15. Gijsbers K., Gouwy M., Struyf S., et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res 2005, 303:331-342.
16. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
17. Ji H., Houghton A.M., Mariani T.J., et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006, 25:2105-2112.
18. Di Carlo E., Forni G., Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy 2003, 83:182-203.
19. Alvarez M.J., Prada F., Salvatierra E., et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 2005, 65:5123-5132.
20. Neville M.E., Pezzella K.M., Schmidt K., Galbraith W., Ackerman N. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. II. Mechanism of inhibition: the role of polymorphonuclear leukocytes. Cytokine 1990, 2:456-463.
21. Souto J.C., Vila L., Bru A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2009, 10.1002/med.20185.
22. Opdenakker G., Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992, 4:251-258.
23. Opdenakker G., Van Damme J. Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 1992, 13:463-464.
24. Fridlender Z.G., Sun J., Kim S., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: " N1" versus " N2" TAN. Cancer Cell 2009, 16:183-194.
25. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
26. Jablonska J., Leschner S., Westphal K., Lienenklaus S., Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010, 120:1151-1164.
27. Houghton A.M. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010, 9:1732-1737.
28. Ferrante A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol Ser 1992, 57:417-436.
29. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
30. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9.
31. Opdenakker G., Fibbe W.E., Van Damme J. The molecular basis of leukocytosis. Immunol Today 1998, 19:182-189.
32. Borregaard N., Sorensen O.E., Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol 2007, 28:340-345.
33. Young M.R., Young M.E., Kim K. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res 1988, 48:6826-6831.
34. Young M.R., Ihm J., Lozano Y., Wright M.A., Prechel M.M. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995, 41:37-45.
35. Sietsma H., Nijhof W., Dontje B., Vellenga E., Kamps W.A., Kok J.W. Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res 1998, 58:4840-4844.
36. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
37. Chioda M., Peranzoni E., Desantis G., et al. Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev 2011, 30:27-43.
38. O'Keane J.C., Wolf B.C., Neiman R.S. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer Res 1989, 63:1539-1543.
39. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
40. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
41. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
42. Movahedi K., Guilliams M., Van den Bossche J., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
43. Balbin M., Fueyo A., Tester A.M., et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003, 35:252-257.
44. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
45. Haqqani A.S., Sandhu J.K., Birnboim H.C. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2000, 2:561-568.
46. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
47. Gerrard T.L., Cohen D.J., Kaplan A.M. Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 1981, 66:483-488.
48. Dallegri F., Patrone F., Frumento G., Sacchetti C. Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 1984, 73:331-339.
49. Katano M., Torisu M. Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 1982, 50:62-68.
50. Lichtenstein A., Seelig M., Berek J., Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood 1989, 74:805-809.
51. Dallegri F., Ottonello L., Ballestrero A., et al. Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation 1991, 15:15-30.
52. Zivkovic M., Poljak-Blazi M., Egger G., Sunjic S.B., Schaur R.J., Zarkovic N. Oxidative burst and anticancer activities of rat neutrophils. Biofactors 2005, 24:305-312.
53. Zivkovic M., Poljak-Blazi M., Zarkovic K., Mihaljevic D., Schaur R.J., Zarkovic N. Oxidative burst of neutrophils against melanoma B16-F10. Cancer Lett 2007, 246:100-108.
54. Sanford M.A., Yan Y., Canfield S.E., et al. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther 2001, 12:1485-1498.
55. Chen Y.L., Wang J.Y., Chen S.H., Yang B.C. Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behaviour. Br J Cancer 2002, 87:359-365.
56. Chen Y.L., Chen S.H., Wang J.Y., Yang B.C. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003, 171:1183-1191.
57. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
58. Kindzelskii A.L., Petty H.R. Early membrane rupture events during neutrophil-mediated antibody-dependent tumor cell cytolysis. J Immunol 1999, 162:3188-3192.
59. Kushner B.H., Cheung N.K. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992, 79:1484-1490.
60. Elsasser D., Stadick H., Stark S., et al. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res 1999, 19:1525-1528.
61. Molema G., Kroesen B.J., Helfrich W., Meijer D.K., de Leij L.F. The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy. J Control Release 2000, 64:229-239.
62. Elsasser D., Valerius T., Repp R., et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996, 87:3803-3812.
63. Piccard H., Van den Steen P.E., Opdenakker G. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol 2007, 81:870-892.
64. Scapini P., Lapinet-Vera J.A., Gasperini S., Calzetti F., Bazzoni F., Cassatella M.A. The neutrophil as a cellular source of chemokines. Immunol Rev 2000, 177:195-203.
65. van Gisbergen K.P., Geijtenbeek T.B., van Kooyk Y. Close encounters of neutrophils and DCs. Trends Immunol 2005, 26:626-631.
66. Giovarelli M., Musiani P., Modesti A., et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995, 155:3112-3123.
67. Di Carlo E., Forni G., Lollini P., Colombo M.P., Modesti A., Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
68. Colombo M.P., Lombardi L., Stoppacciaro A., et al. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. J Immunol 1992, 149:113-119.
69. Musiani P., Modesti A., Giovarelli M., et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 1997, 18:32-36.
70. Cavallo F., Giovarelli M., Gulino A., et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992, 149:3627-3635.
71. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
72. Loges S., Roncal C., Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009, 7:21-33.
73. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
74. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008, 11:215-221.
75. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
76. Nyberg P., Salo T., Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008, 13:6537-6553.
77. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103:12493-12498.
78. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
79. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007, 104:20262-20267.
80. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I., Quigley J.P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 2009, 284:25854-25866.
81. Masson V., de la Ballina L.R., Munaut C., et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005, 19:234-236.
82. Ventura M.T., Cerri A., Jirillo E., Antonaci S., Bonomo L. Human melanoma metastasis culture supernatant contains chemotactic factors for phagocytes. J Clin Lab Anal 1991, 5:21-24.
83. Welch D.R., Schissel D.J., Howrey R.P., Aeed P.A. Tumor-elicited polymorphonuclear cells, in contrast to " normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci USA 1989, 86:5859-5863.
84. Mareel M., Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003, 83:337-376.
85. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442.
86. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579.
87. Masure S., Proost P., Van Damme J., Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 1991, 198:391-398.
88. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
89. Opdenakker G., Van den Steen P.E., Dubois B., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001, 69:851-859.
90. Gilbert L.A., Hermann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
91. Aoudjit F., Masure S., Opdenakker G., Potworowski E.F., St-Pierre Y. Gelatinase B: (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer 1999, 82:743-747.
92. Edwards D.R., Murphy G., Reynolds J.J., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987, 6:1899-1904.
93. Schrötzlmair F., Kopitz C., Halbgewachs B., et al. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med 2010, 14:2760-2770.
94. Gutierrez-Fernandez A., Fueyo A., Folgueras A.R., et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 2008, 68:2755-2763.
95. Overall C.M., Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6:227-239.
96. Sun Z., Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004, 5:182-190.
97. Houghton A.M., Rzymkiewicz D.M., Ji H., et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010, 16:219-223.
98. Sato T., Takahashi S., Mizumoto T., et al. Neutrophil elastase and cancer. Surg Oncol 2006, 15:217-222.
99. Tong Z., Kunnumakkara A.B., Wang H., et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 2008, 68:6100-6108.
100. Wislez M., Antoine M., Rabbe N., et al. Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res 2007, 13:3518-3527.
101. Glaves D. Role of polymorphonuclear leukocytes in the pulmonary clearance of arrested cancer cells. Invasion Metastasis 1983, 3:160-173.
102. Yui S., Tomita K., Kudo T., Ando S., Yamazaki M. Induction of multicellular 3-D spheroids of MCF-7 breast carcinoma cells by neutrophil-derived cathepsin G and elastase. Cancer Sci 2005, 96:560-570.
103. Slattery M.J., Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer 2003, 106:713-722.
104. Liang S., Slattery M.J., Dong C. Shear stress and shear rate differentially affect the multi-step process of leukocyte-facilitated melanoma adhesion. Exp Cell Res 2005, 310:282-292.
105. Dong C., Slattery M.J., Liang S., Peng H.H. Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Mol Cell Biomech 2005, 2:145-159.
106. Peng H.H., Liang S., Henderson A.J., Dong C. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 2007, 313:551-559.
107. Zhang P., Ozdemir T., Chung C.Y., Robertson G.P., Dong C. Sequential binding of alpha(v)beta3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J Immunol 2011, 186:242-254.
108. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 2010, 70:6071-6082.
109. Acuff H.B., Carter K.J., Fingleton B., Gorden D.L., Matrisian L.M. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res 2006, 66:259-266.
110. van den Tol M.P., Ten Raa S., van Grevenstein W.M., van Rossen M.E., Jeekel J., van Eijck C.H. The post-surgical inflammatory response provokes enhanced tumour recurrence: a crucial role for neutrophils. Dig Surg 2007, 24:388-394.
111. Kousis P.C., Henderson B.W., Maier P.G., Gollnick S.O. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 2007, 67:10501-10510.
112. Shojaei F., Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008, 68:5501-5504.
113. Breitbach C.J., Paterson J.M., Lemay C.G., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15:1686-1693.
114. Colombo M.P., Lombardi L., Melani C., et al. Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors. Am J Pathol 1996, 148:473-483.
115. Noffz G., Qin Z., Kopf M., Blankenstein T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J Immunol 1998, 160:345-350.
116. Musiani P., Allione A., Modica A., et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996, 74:146-157.